HLX58 / Fosun Pharma, Shanghai Henlius Biotech - LARVOL DELTA

Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models. (PubMed, Int J Nanomedicine) - "131I-HLX58-Der demonstrated no toxic effects on hepatorenal function, routine blood tests, or major organs in mice when compared to the control group. These findings validate the potential of RADCs targeting CLDN18.2 in treating CLDN18.2-expressing solid tumors."

Journal • Preclinical • Gastric Cancer • Oncology • Solid Tumor • CLDN18

Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate-131I-HLX-58-Deruxtecan for the Precision Treatment of Gastric Cancer (EANM 2024) - "131I-HLX-58-Deruxtecan displayed a significant CLDN18.2 positive tumor affinity and effective tumor therapy without significant toxicity. Therefore, the RADC-131I-HLX-58-Deruxtecan could be further investigated in the theranostic field of gastric cancer."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • TOP1